Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Investigations of the human endocannabinoid system in two subcutaneous adipose tissue depots in lean subjects and in obese subjects before and after weight loss

International Journal of Obesity volume 35, pages 1377–1384 (2011)Cite this article

Subjects

Abstract

Context:

Endocannabinoids (ECs) have a role in obesity by affecting appetite and through peripheral effects. Obesity is associated with a dysregulation of the endocannabinoid system (ECS).

Objective:

We aimed to determine the ECS in subcutaneous adipose tissue (AT) in obese subject and investigate the influence of diet-induced weight loss on this system.

Design:

The obese study participants underwent a 12 weeks diet regimen resulting in 10–12% weight loss. All study participants underwent fasting blood samples and AT biopsies from abdomen and gluteal region, the obese subjects both before and after weight loss.

Setting and participants:

A total of 21 healthy obese individuals (10 men/11 women, age 39.5±1.6 years, body mass index (BMI): 37.5±0.8 kg m−2) and 21 age- and gender-matched lean subjects (BMI: 23.8±0.4 kg m−2) were studied.

Main outcome measures:

The activity of ECS in AT was determined by measuring arachidonoyl glycerol (2-AG) and N-arachidonoylethanolamine/anandamide in AT by mass spectrometry and gene expressions of enzymes and receptors involved in the ECS.

Results:

The EC, 2-AG was reduced in obese individuals in the gluteal AT depot (P<0.01). Moreover, 2-AG increased in both depots in the obese subjects following weight loss (P<0.05). The gene expression of the CB1 was either not affected by the obese state (in the gluteal AT depot) or reduced (in the abdominal depot, P<0.05) and significantly affected by weight loss. The expression of the degrading enzymes FAAH, FAAH2, MGL and MGL2 was differently affected by obesity, AT depot and weight loss.

Conclusion:

We found reduced levels of 2-AG in subcutaneous AT in obesity, which increased after weight loss. In abdominal AT, the low CB1 expression was normalised after weight loss, whereas in gluteal AT the CB1 expression was reduced after weight loss. These findings support the concept of a dysregulated ECS in AT in association with obesity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005; 54: 2838–2843.

    Article  CAS  PubMed  Google Scholar 

  2. Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, Batkai S et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006; 55: 3053–3060.

    Article  PubMed  Google Scholar 

  3. Cote M, Matias I, Lemieux I, Petrosino S, Almeras N, Despres JP et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 2007; 31: 692–699.

    Article  CAS  Google Scholar 

  4. Sipe JC, Scott TM, Murray S, Harismendy O, Simon GM, Cravatt BF et al. Biomarkers of endocannabinoid system activation in severe obesity. PLoS ONE 2010; 5: e8792.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Maccarrone M, Gasperi V, Catani MV, Diep TA, Dainese E, Hansen HS et al. The endocannabinoid system and its relevance for nutrition. Ann Rev Nutr 2010; 30: 423–440.

    Article  CAS  Google Scholar 

  6. Sarzani R, Bordicchia M, Marcucci P, Bedetta S, Santini S, Giovagnoli A et al. Altered pattern of cannabinoid type 1 receptor expression in adipose tissue of dysmetabolic and overweight patients. Metabolism 2009; 58: 361–367.

    Article  CAS  PubMed  Google Scholar 

  7. Di Marzo V . The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 2008; 51: 1356–1367.

    Article  CAS  PubMed  Google Scholar 

  8. Bordicchia M, Battistoni I, Mancinelli L, Giannini E, Refi G, Minardi D et al. Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans. Metabolism 2010; 59: 734–741.

    Article  CAS  PubMed  Google Scholar 

  9. Pertwee RG, Howlett AC, Abood ME, Alexander SPH, Di Marzo V, Elphick MR et al. International Union of Pharmacology. Cannabinoid Receptors and their Ligands: Beyond CB1 and CB2 . Pharmacol Rev 2010; 62: 588–631.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K . GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci USA 2008; 105: 2699–2704.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Matias I, Di Marzo V . Endocannabinoid synthesis and degradation, and their regulation in the framework of energy balance. J Endocrinol Invest 2006; 29 (3 Suppl): 15–26.

    CAS  PubMed  Google Scholar 

  12. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54: 161–202.

    Article  CAS  PubMed  Google Scholar 

  13. Roche R, Hoareau L, Bes-Houtmann S, Gonthier MP, Laborde C, Baron JF et al. Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochem Cell Biol 2006; 126: 177–187.

    Article  CAS  PubMed  Google Scholar 

  14. Ahn K, McKinney MK, Cravatt BF . Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 2008; 108: 1687–1707.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Sugiura T, Kishimoto S, Oka S, Gokoh M . Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog Lipid Res 2006; 45: 405–446.

    Article  CAS  PubMed  Google Scholar 

  16. Hansen HS, Diep TA . N-acylethanolamines, anandamide and food intake. Biochem Pharmacol 2009; 78: 553–560.

    Article  CAS  PubMed  Google Scholar 

  17. De Petrocellis L, Di Marzo V . An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract Res Clin Endocrinol Metab 2009; 23: 1–15.

    Article  CAS  PubMed  Google Scholar 

  18. Kirkham TC, Tucci SA . Endocannabinoids in appetite control and the treatment of obesity. CNS Neurol Disord Drug Targets 2006; 5: 272–292.

    Article  CAS  PubMed  Google Scholar 

  19. Rosenson RS . Role of the endocannabinoid system in abdominal obesity and the implications for cardiovascular risk. Cardiology 2009; 114: 212–225.

    Article  CAS  PubMed  Google Scholar 

  20. Greenberg I, Kuehnle J, Mendelson JH, Bernstein JG . Effects of marihuana use on body weight and caloric intake in humans. Psychopharmacology (Berl) 1976; 49: 79–84.

    CAS  Google Scholar 

  21. Williams CM, Kirkham TC . Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 1999; 143: 315–317.

    Article  CAS  Google Scholar 

  22. Curioni C, Andre C . Rimonabant for overweight or obesity. Cochrane Database Syst Rev 2006; CD006162.

  23. Bennetzen MF, Nielsen TS, Paulsen SK, Bendix J, Fisker S, Jessen N et al. Reduced cannabinoid receptor 1 protein in subcutaneous adipose tissue of obese. Eur J Clin Invest 2010; 40: 121–126.

    Article  CAS  PubMed  Google Scholar 

  24. Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005; 19: 1567–1569.

    Article  CAS  PubMed  Google Scholar 

  25. Pagano C, Pilon C, Calcagno A, Urbanet R, Rossato M, Milan G et al. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab 2007; 92: 4810–4819.

    Article  CAS  PubMed  Google Scholar 

  26. Christiansen T, Paulsen SK, Bruun JM, Ploug T, Pedersen SB, Richelsen B . Diet-induced weight loss and exercise alone and in combination enhance the expression of adiponectin receptors in adipose tissue and skeletal muscle, but only diet-induced weight loss enhanced circulating adiponectin. J Clin Endocrinol Metab 2010; 95: 911–919.

    Article  CAS  PubMed  Google Scholar 

  27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC . Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.

    Article  CAS  PubMed  Google Scholar 

  28. Systéme International (SI) units for plasma, serum, or blood concentrations. Diabetes 1993; 42: 370–371.

  29. Artmann A, Petersen G, Hellgren LI, Boberg J, Skonberg C, Nellemann C et al. Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine. Biochim Biophys Acta 2008; 1781: 200–212.

    Article  CAS  PubMed  Google Scholar 

  30. Matias I, Gonthier MP, Orlando P, Martiadis V, De PL, Cervino C et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006; 91: 3171–3180.

    Article  CAS  PubMed  Google Scholar 

  31. Starowicz KM, Cristino L, Matias I, Capasso R, Racioppi A, Izzo AA et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring) 2008; 16: 553–565.

    Article  CAS  Google Scholar 

  32. Izzo AA, Piscitelli F, Capasso R, Aviello G, Romano B, Borrelli F et al. Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding. Br J Pharmacol 2009; 158: 451–461.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le FG, Oury-Donat F et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63: 908–914.

    Article  CAS  PubMed  Google Scholar 

  34. Annuzzi G, Piscitelli F, Di Marino L, Patti L, Giacco R, Costabile G et al. Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients. Lipids Health Dis 2010; 9: 43.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Engeli S, Heusser K, Janke J, Gorzelniak K, Batkai S, Pacher P et al. Peripheral endocannabinoid system activity in patients treated with sibutramine. Obesity (Silver Spring) 2008; 16: 1135–1137.

    Article  CAS  Google Scholar 

  36. Di Marzo V, Cote M, Matias I, Lemieux I, Arsenault BJ, Cartier A et al. Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia 2009; 52: 213–217.

    Article  CAS  PubMed  Google Scholar 

  37. Di Marzo V, Maccarrone M . FAAH and anandamide: is 2-AG really the odd one out? Trends Pharmacol Sci 2008; 29: 229–233.

    Article  CAS  PubMed  Google Scholar 

  38. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S et al. Activation of the peripheral endocannabinoid system in human obesity Diabetes 2005; 54: 2838–2843.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank all study participants. We greatly appreciate the excellent technical assistance of Lenette Pedersen and Pia Hornbek, Department of Endocrinology, Aarhus University Hospital. The study was supported by the Danish Medical Research Council, Aarhus University, Danish Obesity Research Centre, DanORC (Danish Strategic Research Council), and by the UNIK project: Food, Fitness, and Pharma.

Author information

Authors and Affiliations

  1. Department of Endocrinology C, Aarhus University Hospital, Aarhus C, Denmark

    M F Bennetzen, B Richelsen & S B Pedersen

  2. Department of Pharmacology and Pharmacotherapy, Faculty of Pharmaceutical Sciences, University of Copenhagen, Copenhagen Ø, Denmark

    N Wellner, S S Ahmed, S M Ahmed, T A Diep & H S Hansen

Authors
  1. M F Bennetzen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N Wellner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S S Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S M Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T A Diep
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H S Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B Richelsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S B Pedersen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M F Bennetzen.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bennetzen, M., Wellner, N., Ahmed, S. et al. Investigations of the human endocannabinoid system in two subcutaneous adipose tissue depots in lean subjects and in obese subjects before and after weight loss. Int J Obes 35, 1377–1384 (2011). https://doi.org/10.1038/ijo.2011.8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijo.2011.8

Keywords

This article is cited by

Search

Advanced search

Quick links